



## Antiphospholipid Antibodies and Syndrome

Guest Editor:

**Prof. Dr. Ricard Cervera**

Department of Autoimmune  
Diseases, Hospital Clinic,  
Barcelona, 08036 Catalonia,  
Spain

Deadline for manuscript  
submissions:

**closed (31 December 2016)**

### Message from the Guest Editor

Dear Colleagues,

Antiphospholipid syndrome (APS) is an autoimmune disorder caused by antiphospholipid antibodies. It was characterized by excessive clotting of blood and/or certain complications of pregnancy (premature miscarriages, unexplained fetal death, or premature birth) and the presence of antiphospholipid antibodies (such as anti-cardiolipin antibodies or lupus anticoagulant) in the blood. Fifty percent of people with lupus have APS. The exact pathogenesis of APS is inadequately understood, so no specific treatment is available.

This Special Issue of *Antibodies* focuses on the symptoms, pathogenesis, diagnosis, clinical manifestation, therapy of APS, the new research development of antiphospholipid antibodies, and all the other aspects of APS.

Prof. Dr. Ricard Cervera  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Arne Skerra

Chair of Biological Chemistry,  
Technical University of Munich,  
Emil-Erlenmeyer-Forum 5, 85354  
Freising (Weihenstephan),  
Germany

## Message from the Editor-in-Chief

*Antibodies* is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** CiteScore - Q1 (*Drug Discovery*)

## Contact Us

*Antibodies* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibodies](http://mdpi.com/journal/antibodies)  
[antibodies@mdpi.com](mailto:antibodies@mdpi.com)  
[X@Antibodies\\_MDPI](https://twitter.com/Antibodies_MDPI)